Mohammed Attallah, founder.

Biomelogic is the consulting practice of an independent researcher working outside the constraints of institutional affiliation. The work is mechanistic in orientation: it begins from first principles in mitochondrial bioenergetics, mucosal immunology, microbial ecology, and epigenetics, and integrates those domains into a single causal framework for analyzing chronic illness.

The work, not the credential

The absence of a formal academic appointment is, in this context, a feature. The intellectual problem at the center of complex chronic illness — that conventional and functional workups continue to treat downstream signatures as primary lesions — is not a problem of insufficient data. It is a problem of organizing frameworks. Working outside an institution leaves the framework unconstrained by departmental boundaries.

Most of what is known about the biology that matters here is already published. The journals are full of it. What has been missing is a synthesis — a unified causal account that crosses the boundaries between gastroenterology, immunology, mitochondrial biology, and epigenetics, and reads them together rather than separately. Producing that synthesis requires sustained attention across domains that are conventionally separated by training, departmental affiliation, and citation network. It is the kind of work the institutional structure of biomedical research is poorly configured to support.

The intellectual contribution

The central contribution of Biomelogic is the Host Capacity Model — a unified causal account of how colonocyte bioenergetic failure, driven by iron-sulfur cluster insufficiency and the CD38–NAD⁺–SIRT3 cascade, propagates through barrier, immune, and metabolic domains to produce the clinical phenotypes recognized as SIBO, MCAS, dysbiosis, and post-viral syndromes.

The model inverts the dominant clinical paradigm. The microbial composition of a compromised gut is not the disease that produced it; it is the readout of a host substrate that has lost the capacity to define its own niche. Restoring the substrate is the work. The microbial composition reorganizes around it.

The full framework is developed at length on the Host Capacity Model page and across the articles.

How the framework developed

The Host Capacity Model is the result of a multi-year project of self-directed research. The starting point was the conventional clinical narrative around SIBO, dysbiosis, and chronic gut dysfunction — and the recognition that the narrative was producing predictable failures: recurrence after antimicrobial treatment, inconsistent response to probiotic re-seeding, and a steadily expanding population of patients accumulating diagnoses faster than treatments. The pattern of failure was the data that demanded a different framework.

The work that followed crossed several territories: the colonocyte metabolism literature anchored in the Bäumler and Litvak studies on physiological hypoxia and Enterobacteriaceae expansion; the iron-sulfur cluster biogenesis literature; the CD38 and NAD⁺ aging biology developed substantially in the Chini and Sinclair groups; the SIRT3 substrate work; the cholinergic anti-inflammatory pathway as characterized by Tracey and colleagues; the epigenetic regulation of SLC5A8; and the mast cell biology that connects barrier failure to the systemic immune signature. Each of these is a developed body of work in its own right. The contribution of Biomelogic is the integration — reading them as a single causal system rather than as independent literatures.

The model is not finished. New mechanisms continue to be added. Some early formulations have been refined or revised. The intent is to publish the formal version through peer-reviewed channels in coordination with practitioners and researchers whose clinical and laboratory work intersects the framework.

The methodology

A Biomelogic consultation is, mechanistically, an HCM re-read of the case. The work is to identify which arm of the substrate failure is dominant in the particular host, what upstream drivers are sustaining it, where the testing data the client has already accumulated points, and what intervention sequencing would address the substrate rather than the readout.

Several features distinguish the methodology:

It is restrained. The framework specifies what it can and cannot account for, and the consultation hands off to other specialists where the dominant lesion sits outside HCM territory. Overreach is the principal failure mode of frameworks of this kind, and the work guards against it.

It is coordinated. Recommendations are mechanistic and educational. Implementation belongs to the client's licensed medical team. Written summaries are intended to be shared with the team, not to operate independently of it.

Language and reach

Mohammed is of Egyptian heritage and writes in both English and Arabic. The practice serves an international readership and accepts international clients.

Biomelogic is not clinical care. Mohammed is not a licensed clinician and does not diagnose, treat, or prescribe. See the scope of practice.